title: [The efficacy of G-CSF and GM-CSF in the adjunctive treatment of infections complicating chemotherapy of solid tumors in children. Report of Polish Pediatric Leukemia/Lymphoma Treatment Group].
abstract: Total number of 306 cycles of GM-CSF-Leucomax Sandoz (5 mg/kg/day s.c.) and/or G-CSF Filgrastim Hoffmann-La Roche (5-10 mg/kg/day s.c.) was applied in 146 children aged from 0.5-18 years during neutropenia associated with chemotherapy of solid tumours. Seventeen children with malignancies served as a historical control group. Our study have demonstrated after both G- and GM-CSF therapy shorter period of neutropenia, reduction of the number of febrile days and a decreased frequency of infectious complications and infection's duration.
authors.affiliation: Kliniki Hematologii i Chorób Rozrostowych Dzieci Akademii Medycznej we Wrocławiu.
authors.forename: A
authors.initials: A
authors.lastname: Chybicka
authors.forename: J
authors.initials: J
authors.lastname: Bogusławska-Jaworska
authors.forename: B
authors.initials: B
authors.lastname: Rosińska
authors.forename: J
authors.initials: J
authors.lastname: Wecławek-Tompol
authors.forename: J
authors.initials: J
authors.lastname: Armata
authors.forename: A
authors.initials: A
authors.lastname: Balcerska
authors.forename: W
authors.initials: W
authors.lastname: Balwierz
authors.forename: H
authors.initials: H
authors.lastname: Bubała
authors.forename: K
authors.initials: K
authors.lastname: Drabko
authors.forename: A
authors.initials: A
authors.lastname: Eliasińska
authors.forename: M
authors.initials: M
authors.lastname: Kedziora
authors.forename: P
authors.initials: P
authors.lastname: Kołecki
authors.forename: J
authors.initials: J
authors.lastname: Kowalczyk
authors.forename: M
authors.initials: M
authors.lastname: Matysiak
authors.forename: A
authors.initials: A
authors.lastname: Płoszyńska
authors.forename: R
authors.initials: R
authors.lastname: Rokicka-Milewska
authors.forename: D
authors.initials: D
authors.lastname: Sońta-Jakimczyk
authors.forename: B
authors.initials: B
authors.lastname: Sopyło
authors.forename: M J
authors.initials: MJ
authors.lastname: Stefaniak
authors.forename: E
authors.initials: E
authors.lastname: Stańczak
authors.forename: D
authors.initials: D
authors.lastname: Stencel
authors.forename: M
authors.initials: M
authors.lastname: Wysocki
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000293:Adolescent; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D007239:Infections / Q000150:complications* / Q000188:drug therapy*; D007938:Leukemia / Q000150:complications* / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D009503:Neutropenia / Q000150:complications*; D011044:Poland; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D016179:Granulocyte Colony-Stimulating Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor